[Disorders of and means of normalizing the deamination of nitrogenous compounds in the liver in experimental neoplasms].
D000227:Adenine Nucleotides / Q000627:therapeutic use; D000249:Adenosine Monophosphate / Q000378:metabolism*; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000378:metabolism*; D002467:Cell Nucleus / Q000378:metabolism; D003641:Deamination; D050356:Lipid Metabolism; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008930:Mitochondria, Liver / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D010293:Pargyline / Q000627:therapeutic use; D010545:Peroxides / Q000378:metabolism; D011700:Putrescine / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*; D014439:Tyramine / Q000378:metabolism*; D014810:Vitamin E / Q000627:therapeutic use
D000227:Adenine Nucleotides; D008996:Monoamine Oxidase Inhibitors; D010545:Peroxides; D014810:Vitamin E; D012701:Serotonin; D000249:Adenosine Monophosphate; D010293:Pargyline; D011700:Putrescine; D014439:Tyramine
Narushenie i puti normalizatsii dezaminirovaniia nekotorykh azotistykh soedeneniĭ v pecheni zhivotnykh-opukholenositeleĭ